A study from W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Department of Pathology, and Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA has reported that IL-17 mediates Inflammatory cardiac diseases.
This study was published in the June 16, 2014 JEM [I.F >15] by Prof. Daniela Čiháková, Lei Wu and others from Johns Hopkins University School of Medicine, Baltimore, MD, USA.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Natural product-based therapeutics for Inflammatory cardiac disease: Cucurbitacin I (JSI-124) inhibits Inflammatory dilated cardiomyopathy (DCMi) via down regulation of its target gene. This study may suggest that Cucurbitacin I (JSI-124), by down regulating its target gene, it may inhibit Inflammatory dilated cardiomyopathy (DCMi). Together, this study suggests that pharmacological formulations encompassing “Cucurbitacin I (JSI-124) or its analogues” can be used in the treatment of Inflammatory cardiac diseases.
Idea Proposed/Formulated by: Dr L Boominathan PhD
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Courtesy: When you cite drop us a line at info@genomediscovery.org
Citation: Boominathan, Natural product-based therapeutics for Inflammatory cardiac disease: Cucurbitacin I (JSI-124) inhibits Inflammatory dilated cardiomyopathy (DCMi) via down regulation of its target gene, 17/July/2014, 8.13 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
*Research cooperation
